Revolutionizing precision heart care
HeartFlow brings together human ingenuity and advanced technology to help combat heart disease, the leading cause of death.

HeartFlow's non-invasive, personalized cardiac test provides unprecedented visualization of each patient's coronary arteries, enabling physicians to create more effective treatment plans for their patients.
By combining review from expert analysts, who have over 500,000 hours of collective experience, with AI-powered algorithms trained on millions of CT images, HeartFlow is bringing a new level of precision to non-invasive detection of heart disease.

- 2x more likely to identify disease than other tests\(^1\)
- Low false negative and false positive rates in real-world clinical use\(^2\)
- “Core Lab” quality control monitoring program with over 10,000 measurements\(^2\)
Since inception, HeartFlow has been committed to producing comprehensive clinical evidence supporting the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of its product portfolio.

With more than 400 publications in prominent peer-reviewed medical journals including JAMA, JACC, Circulation, the American Journal of Cardiology, and Heart, the HeartFlow technology has been proven across diverse patient populations. These clinical activities have included a series of large, multi-center global trials encompassing over 10,000 patients worldwide.

**ROBUST EVIDENCE**

- 16 clinical trials and registries addressing accuracy and outcomes
- 100+ investigator-initiated studies
- 400+ peer-reviewed publications
- Demonstrated safety with long-term data out to 5 years

**AREAS OF RESEARCH**

- Pre-TAVR
- ACS - NSTEMI
- Heart Transplant
- Emergency Department
- Pre-operative Cardiac Evaluation
- Preventative Screening
- Pediatrics
- Neurovascular
- Renal Failure
- PAD

*HeartFlow is interested in exploring the use of FFRct in these populations*
Exceptional Clinical Results

Time and time again, HeartFlow demonstrates unmatched non-invasive diagnostic performance and accuracy, alongside cost-effectiveness and efficacy.

- Higher diagnostic accuracy than other common non-invasive cardiac tests\(^3\)
- 83% of avoidable coronary angiograms cancelled\(^4\)
- 36% improvement in revascularization efficiency\(^5\)
- 40% reduction in layered testing\(^5\)
- Dominates functional testing in cost-effectiveness analysis\(^6\)
Best-in-class Technology

- Patient-specific Interactive 3D Model
- Best-in-class medical image analysis
- Advanced deep learning (AI) methodology to precisely extract coronary anatomy
- AI trained on millions of CT images carefully annotated by expert analysts
- Physics-based computational models assess pressure and flow changes in coronary arteries
- HIPAA and SOC 2 Type II compliant, HITRUST certified
- Secure cloud infrastructure, including encrypted transmission of image data and protected health information (PHI)
- Comprehensive IP portfolio of > 370 issued and allowed patents worldwide, covering innovations in cardiovascular medicine, physiology and bioengineering
Bringing together human ingenuity and advanced technology, HeartFlow is developing an integrated solution for comprehensive management of coronary artery disease (CAD). From precise diagnostics to treatment optimization, HeartFlow’s integrated solution will shape cardiac care.

**CAD Diagnosis**
- **CORONARY STENOSIS***
  - Stenosis and Image Quality Data for all CTA patients

**CAD Severity Assessment**
- **INTERACTIVE FFRct***
  - Anatomy and physiology via personalized 3D model
- **MYOCARDIAL INSIGHTS***
  - % Myocardium Affected, Myocardial Perfusion Data

**CAD Treatment Optimization**
- **PLAQUE ANALYSIS***
  - Plaque Visualization and Quantification
- **INTERVENTION PLANNING***
  - Planning Cath Procedures & Virtual Revascularization

*Currently in development and not available for clinical use.
Outstanding Customer Experience

93% Customer Satisfaction

FAST
<5 hour turnaround time²

SEAMLESS
IT integrations streamline workflows

EDUCATION
CTA program and image quality training resources

SECURE
Ongoing security and software updates

ECONOMICAL
No inventory or capital purchase

SUPPORT
Dedicated team to facilitate favorable reimbursement
HeartFlow is Leading the Way

» Secured regulatory clearance to commercialize first-of-kind, AI-enabled, non-invasive diagnostic simulation of FFR_{CT} (2011: CE Mark, 2014: US FDA De Novo Clearance, 2017: Japan PMDA approval)

» Established Medicare New Technology Ambulatory Payment Classification to reimburse hospitals, effective Jan 1, 2018

» 92% of people in the US have insurance coverage for HeartFlow

» 70,000+ patients received a HeartFlow Analysis

» Adopted by over 350 hospitals worldwide, including 75% of the top 50 heart hospitals in the US^7
REFERENCES


7. Top 50 Heart Hospitals as designated by US News and World Report